Results 101 to 110 of about 27,256 (249)

A metformin-monoterápia és a szitagliptin/metformin fix kombináció egyéves perzisztenciája [PDF]

, 2016
Absztrakt Bevezetés: A 2-es típusú cukorbetegség kezelésében fontos a glykaemiás célok elérése. Ennek fontos tényezője a diéta mellett a gyógyszeres kezelés terápiahűsége.
Ferenci, Tamás, Simonyi, Gábor
core   +1 more source

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1304-1314, February 2026.
Abstract Aim PIONEER REAL Saudi Arabia investigated real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes (T2D). Materials and Methods This was a 34‐ to 44‐week multicentre, prospective, open‐label study in adults with T2D, who were treatment‐naive to injectable glucose‐lowering medication ...
Hussein ElBadawi, Nader Albalkhi, Ibrahim Al Kadhim, Ahmed Elsadig, Dimitrios Baltzis, Mohamed Hassan Hatahet, Mahmoud Ismail, Said Khader, Christina Louise Rasmussen, Stine Hedegaard Scheuer, Ahmed Shalaby, Mohammed Almehthel   +11 more
wiley   +1 more source

A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study [PDF]

, 2021
Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro   +8 more
openalex   +1 more source

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1443-1452, February 2026.
Abstract Objective This study provides real‐world evidence on the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM).
Filippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, Georgia Anastasiou, Christos S. Mantzoros   +4 more
wiley   +1 more source

The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. [PDF]

, 2013
The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively ...
Chakraborty, Sandeep, Dandekar, Abhaya M, Dutta, Mouparna, Ghosh, Anindya S, Goñi, Félix M, Oda, Masataka, Rao, Basuthkar J, Rendón-Ramírez, Adela, Venkatramani, Ravindra, Ásgeirsson, Bjarni   +9 more
core  

Inhibition of DPP4/CD26 and dmPGE2 treatment enhances engraftment of mouse bone marrow hematopoietic stem cells [PDF]

, 2014
Enhancing the engraftment of hematopoietic stem cells (HSC) is especially important when times to engraftment are prolonged due either to limiting numbers of HSC in the donor graft or to intrinsic slower engrafting time of the tissue sources of HSC. Both
Broxmeyer, Hal E., Pelus, Louis M.
core   +1 more source

Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2 +/− rat model

Journal of Neuroinflammation
Impaired function of the retinal neurovascular unit (NVU) is an early event in diabetic retinopathy (DR). It has been previously shown that topical delivery of the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin can protect against diabetes-mediated
Hugo Ramos, Josy Augustine, Burak M. Karan, Cristina Hernández, Alan W. Stitt, Tim M. Curtis, Rafael Simó   +6 more
doaj   +1 more source

Effect of Sitagliptin as Add-on Therapy in Elderly Type 2 Diabetes Patients With Inadequate Glycemic Control in Taiwan

International Journal of Gerontology, 2011
Background: To evaluate the effectiveness and tolerability of add-on sitagliptin in elderly Taiwanese patients with Type 2 diabetes mellitus who have inadequate glycemic control to existing oral antidiabetic agents (OADs) combination regimens.
Ming-Nan Chien, Chun-Chuan Lee, Wei-Che Chen, Sung-Chen Liu, Ching-Hsiang Leung, Chao-Hung Wang   +5 more
doaj   +1 more source

RNA‐Seq Analysis of the Liver Transcriptome Reveals the Networks Regulating Treatment of Sitagliptin Phosphate plus Fuzhujiangtang Granule in the Zucker Diabetic Fatty Rats [PDF]

, 2020
Xuan Guo, Wen Sun, Guangyuan Xu, Dan Hou, Zhuo Zhang, Lili Wu, Tonghua Liu   +6 more
openalex   +1 more source

Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: Role of GLP-1 isoforms in Glut4 receptor trafficking [PDF]

, 2018
Background: The distribution of glucose and fatty-acid transporters in the heart is crucial for energy consecution and myocardial function. In this sense, the glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, improves glucose homeostasis but it ...
Caro-Vadillo, A., Cruz, F., Egido, J., González-Bris, A., Lorenzo, Ó., Morcillo, M. A., Oteo, M., Picatoste, Belén, Ramírez, E., Tuñón, J.   +9 more
core   +2 more sources